This week Dr. Evan Loh, Paratek CEO, returns to Off theShelf to share the latest in the biopharmaceutical company’s partnership withthe Biomedical Advanced Research and Development Authority’s (BARDA’s) Project BioShield. Paratek’s antibiotic, NUZYRA (omadacycline) has beendesignated “an essential” medicine by the FDA, and Loh provides an updateon the progress made in onshoring of manufacturing of NUZYRA, from theproduction of API through finished drug product for both IV and oralformulations. Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek’s public-private partnership with BARDA played in developing manufacturing capability.Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations incombatting these and other healthcare threats. Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protectthe warfighter.    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ver todos los episodios